| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Ganoderic acid G targets multiple signaling pathways involved in cancer. It primarily targets NF-κB, RAS-MAPK, and the PI3K/Akt/mTOR pathways. It modulates the signaling network in IR, IGFR-1, VEGFR-2, and ER in cancer signaling pathways. By modulating these pathways, it inhibits tumor cell proliferation and induces apoptosis. It also exhibits anti-inflammatory activity by inhibiting the production of nitric oxide (NO) in LPS-induced BV-2 microglial cells with an IC50 of 5.77 µM.
|
|---|---|
| ln Vitro |
In vitro, Ganoderic acid G has demonstrated significant anticancer activity. It decreases the viability, proliferation, and oxidative stress in a dose-dependent manner in liver cancer cells. It exhibits anti-inflammatory activity by inhibiting NO production in microglial cells. These activities suggest that Ganoderic acid G can modulate key signaling pathways involved in cancer and inflammation.
|
| ln Vivo |
In vivo, Ganoderic acid G has demonstrated significant anticancer potential by inhibiting tumor growth and inducing apoptosis. It has been investigated for its potential in treating liver diseases, cardiovascular disorders, and immune-related conditions. However, specific in vivo efficacy data are not extensively documented in the public literature. Further studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
For in vitro enzyme and cell-based assays, the activity of Ganoderic acid G can be assessed. Its effects on NF-κB, MAPK, and PI3K/Akt signaling can be studied by Western blotting for phosphorylated proteins. Its anti-inflammatory activity can be measured by quantifying NO production in LPS-stimulated BV-2 microglial cells using the Griess reagent. Its anticancer activity can be evaluated in liver cancer cell lines by measuring cell viability and apoptosis.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines, such as liver cancer cells, are cultured and treated with Ganoderic acid G. Cell viability is measured using MTT or CCK-8 assays. Apoptosis is assessed by Annexin V staining. The compound's effects on cell signaling pathways are studied by Western blotting. Its anti-inflammatory effects are evaluated in microglial cells by measuring NO and cytokine production.
|
| Animal Protocol |
For in vivo animal studies, Ganoderic acid G is typically administered orally or intraperitoneally in rodent models of cancer or inflammation. Xenograft models of liver cancer can be used to evaluate its antitumor efficacy. Tumor-bearing mice are treated with the compound, and tumor growth is monitored. Its effects on inflammation can be studied in models of acute or chronic inflammation.
|
| ADME/Pharmacokinetics |
Ganoderic acid G has a molecular weight of 572.7. As a triterpenoid, it is expected to have poor oral bioavailability. Detailed pharmacokinetic parameters, such as half-life and tissue distribution, are not publicly available. It is typically stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Ganoderic acid G are limited. As a natural compound from Ganoderma lucidum, which has a long history of use in traditional medicine, it is generally considered to have a favorable safety profile. However, comprehensive toxicological studies have not been published. The compound is used for research purposes only and is not intended for human use.
|
| References | |
| Additional Infomation |
Reports have indicated that Ganoderma lucidum contains ganoderic acid G, and relevant data is available for reference.
Ganoderic acid G is a research compound with no clinical trial or regulatory approval status. It is a natural product isolated from Ganoderma lucidum and is used as a research tool to study cancer and inflammation pathways. It is commercially available from chemical suppliers for research purposes only. |
| Molecular Formula |
C30H44O8
|
|---|---|
| Molecular Weight |
532.6656
|
| Exact Mass |
532.304
|
| CAS # |
98665-22-6
|
| PubChem CID |
20055988
|
| Appearance |
White to off-white solid powder
|
| Density |
1.27g/cm3
|
| Boiling Point |
722.7ºC at 760 mmHg
|
| Melting Point |
218 - 220 °C
|
| Flash Point |
404.8ºC
|
| Index of Refraction |
1.575
|
| LogP |
3.102
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@H](CC(=O)CC(C)C(=O)O)[C@H]1CC(=O)[C@@]2([C@@]1([C@@H](C(=O)C3=C2[C@H](C[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)O)C)C
|
| InChi Key |
BPJPBLZKOVIJQD-YYFGTHFASA-N
|
| InChi Code |
InChI=1S/C30H44O8/c1-14(10-16(31)11-15(2)26(37)38)17-12-21(34)30(7)22-18(32)13-19-27(3,4)20(33)8-9-28(19,5)23(22)24(35)25(36)29(17,30)6/h14-15,17-20,25,32-33,36H,8-13H2,1-7H3,(H,37,38)/t14-,15?,17-,18+,19+,20+,25-,28+,29+,30+/m1/s1
|
| Chemical Name |
(6R)-2-methyl-4-oxo-6-[(3S,5R,7S,10S,12S,13R,14R,17R)-3,7,12-trihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~187.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8773 mL | 9.3867 mL | 18.7733 mL | |
| 5 mM | 0.3755 mL | 1.8773 mL | 3.7547 mL | |
| 10 mM | 0.1877 mL | 0.9387 mL | 1.8773 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
